BEVERLY, Mass., Oct. 19, 2009 (GLOBE NEWSWIRE) — Cellceutix Corporation (OTCBB:CTIX) today announced that data recently presented by the Company at the American Association for Cancer Research (AACR) along with other data developed by the Company indicate that Kevetrin is selectively targeting very specific anti-tumor pathways, such as AKT and p38 MAP kinase. The data presented at the AACR showed that Kevetrin was less cytotoxic than paclitaxel, cisplatin and 5FU while having better anti-tumor activity in two multi-drug resistant lung cancer cell lines. This indicates that Kevetrin is not acting primarily as a cytotoxic agent but may be targeting specific components of the signal transduction pathway, such as AKT and p38 MAP kinase. The Company is continuing to explore other potential targets.

Other data developed by the Company indicate that Kevetrin has potent anti-tumor activity in one cell line (MDA-MB–231) despite only partially inhibiting AKT in that cell line.

...

Kevetrin(TM) Shows Excellent Activity in Animal Models of Drug Resistant Lung Cancer With Less Cytotoxicity Than Paclitaxel

Cellceutix of Beverly, MA, to Pursue Development for Drug-Resistant Lung Cancer

BEVERLY, Mass., Oct. 13, 2009 (GLOBE NEWSWIRE) — Cellceutix Corporation (OTCBB:CTIX) today announced that it presented a poster and its Chief Scientific Officer, Dr. Krishna Menon, was one of only four individuals selected to participate in an expert panel discussion of the abstract at the American Association for Cancer Research (AACR) meeting “Frontiers in Basic Cancer Research” in Boston, MA on October 10, 2009. The Company’s poster describes in vitro and in vivo research on its lead compound, Kevetrin(TM), which is being developed for drug resistant cancers. The three day AACR meeting featured presentations on the latest advances in basic cancer research from around the world. The AACR issued a press release on October 10, 2009 which featured the abstract submitted

...

Provectus Pharmaceuticals, Inc.

(Public, OTC:PVCT)

StocksHaven Investments profiles one of the most exciting up-and-coming anti-cancer companies in the industry, Provectus Pharmaceuticals (OTC:PVCT). They have one of the deepest pipelines of any small cap biotech, focusing on treatments for: Melanoma, Psoriasis, Atopic Dermatitis, Breast Cancer, and Liver Metastasis. With three drugs nearly ready to enter Phase III, including one nearly entering Phase II for Breast Cancer, one of the largest target markets worldwide and seeking “compassionate use” in Australia and USA, look for Provectus to make a splash within the next couple of months.

They are developing and testing one of the most exciting anti- cancer compounds. It has been demonstrating significant effectiveness against Melanoma in Phase 2 clinical trials and it offers promising treatment for breast, liver and other solid tumor based metastatic cancers. The compound developed by Provectus, known as PV-10, is a

...